Lipoprotein-associated oxidative stress: A new twist to the postprandial hypothesis

International Journal of Molecular Sciences

Volumn 16, Issue 1, 2014, Pages 401-419

  Le, Ngoc Anh ^a  

^a ATLANTA VA MEDICAL CENTER   (United States)

Author keywords

Lipoproteins; Oxidative stress; Postprandial lipemia; Reactive oxygen species

Indexed keywords

APOLIPOPROTEIN B; EPITOPE; GLUCOSE; INSULIN; OXIDIZED LOW DENSITY LIPOPROTEIN; POLYUNSATURATED FATTY ACID; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; TRIACYLGLYCEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PLASMA PROTEIN;

ARTERY WALL; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CELL METABOLISM; CELLULAR STRESS RESPONSE; CHEMICAL MODIFICATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPOTHESIS; LIPID PEROXIDATION; LIPID STORAGE; LIPOPROTEIN BLOOD LEVEL; OXIDATIVE STRESS; POSTPRANDIAL STATE; REVIEW; RISK FACTOR; VASCULARIZATION; ANIMAL; METABOLISM;

ANIMALS; ATHEROSCLEROSIS; BLOOD PROTEINS; HUMANS; LIPOPROTEINS; LIPOPROTEINS, LDL; OXIDATIVE STRESS; POSTPRANDIAL PERIOD; REACTIVE OXYGEN SPECIES;

EID: 84919928201     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms16010401     Document Type: Review

References (115)

1. Zorov, D.B.; Juhaszova, M.; Sollott, S.J., Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release. Physiol. Rev. 2014, 94, 909–950.
2. Farkas-Epperson, M.; Le, N.-A. Lipoproteins as biosensors of endothelial oxidative stress. Clin. Lipidol. 2012, 7, 49–63.
3. Libby, P.; Ridker, P.M.; Maseri, A. Inflammation and atherosclerosis. Circulation 2002, 105, 1135–1143.
4. Van Oostrom, A.J.H.H.M.; van Wijk, J.P.H.; Castro-Cabezas, M. Lipemia, inflammation and atherosclerosis: Novel opportunities in the understanding and treatment of atherosclerosis. Drugs 2004, 64, 19–24.
5. Goldstein, J.L.; Ho, Y.K.; Basu, S.K.; Brown, M.S., Binding sites on macrophages that mediates uptake and degradation of acetylated LDL, producing massive cholesterol deposition. Proc. Natl. Acad. Sci.1979, 76, 333–337.
6. Fogelman, A.M.; Schechter, I.; Seager, J.; Hokom, M.; Child, J.S.; Edwards, P.A. Malondialdehyde alteration of low density lipoproteins leads to cholesteryl ester accumulation in human monocyte-macrophages. Proc. Natl. Acad. Sci. USA 1980, 77, 2214–2218.
7. Navab, M.; Hama, S.H.; Ready, S.T.; Ng, C.J.; van Lenten, B.J.; Laks, H.; Fogelman, A.M. Oxidized lipids as mediators of coronary heart disease. Curr. Opin. Lipidol. 2002, 13, 363–372.
8. Palinski, W.; Rosenfeld, M.E.; Yla-Herttuala, S.; Gurtner, G.C.; Socher, S.S.; Butler, S.W.; Parthasarathy, S.; Carew, T.E.; Steinberg, D.; Witztum, J.L. LDL undergoes oxidative modification in vivo. Proc. Natl. Acad. Sci. USA 1989, 86, 1372–1376.
9. Avogaro, P.; Bon, G.B.; Cazzolato, G. Presence of a modified LDL in humans. Arteriosclerosis 1988, 8, 79–87.
10. Yla-Herttuala, S.; Palinski, W.; Rosenfeld, M.E.; Parthasarathy, S.; Carew, T.E.; Butler, S.; Witztum, J.L.; Steinberg, D. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J. Clin. Investig. 1989, 84, 1086–1095.
11. Holvoet, P.; Vanhaecke, J.; Janssens, S.; van de Werf, F.; Collen, D. Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation 1998, 98, 1487–1494.
12. Hulthe, J.; Fagerberg, B., Circulating oxidized LDL is associated with subclinical atherosclerosis development and inflammatory cytokines (AIR study). Arterioscler. Thromb. Vasc. Biol. 2002, 22, 1162–1167.
13. Ishigaki, Y.; Oka, Y.; Katagiri, H. Circulating oxidized LDL: A biomarker and a pathogenic factor. Curr. Opin. Lipidol. 2009, 20, 363–369.
14. Itabe, H. Oxidized low-density lipoproteins: What is understood and what remains to be clarified. Biol. Pharm. Bull. 2003, 26, 1–9.
15. Steinberg, D.; Parthasarathy, S.; Carew, T.E.; Khoo, J.C.; Witztum, J.L. Beyond cholesterol: Modifications of low-density lipoprotein that increase its atherogenecity. N. Engl. J. Med. 1989, 320, 915–924.
16. Witztum, J.L.; Steinberg, D. Role of oxidized low density lipoprotein in atherogenesis. J. Clin. Investig. 1991, 88, 1785–1792.
17. Steinberg, D.; Witztum, J.L. Oxidized low-density lipoprotein and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2010, 30, 2311–2316.
18. Chisolm, G.M.; Steinburg, D. The oxidative modification hypothesis of atherogenesis: An overview. Free Radic. Biol. Med. 2000, 28, 1815–1826.
19. Sigurdardottir, V.; Fagerberg, B.; Hulthe, J..Circulating oxidized low-density lipoprotein (LDL) is associated with risk factors of the metabolic syndrome and LDL size in clinically healthy 58-year-old men (AIR study). J. Intern. Med. 2002, 252, 440–447.
20. Shimada, K.; Mokuno, H.; Matsunaga, E.; Miyazaki, T.; Sumiyoshi, K.; Miyauchi, K.; Daida, H. Circulating oxidized LDL is an independent predictor for cardiac event in patients with coronary artery disease. Atherosclerosis 2004, 174, 343–347.
21. Memon, R.; Staprans, I.; Noor, M..Infection and inflammation induce LDL oxidation in vivo. Arterioscler. Thromb. Vasc. Biol. 2000, 20, 1536–1540.
22. Pearson, T.A.; Mensah, G.A.; Alexander, R.W.; Anderson, J.L.; Canno, R.O., III; Criqui, M.; Fadl, Y.Y.; Fortmann, S.P.; Hong, Y.; Myer, G.L.; et al., Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the centers for disease control and prevention and the american heart association. Circulation 2003, 107, 499–511.
23. Szmitko, P.E.; Wang, C.H.; Weisel, R.D.; Jeffries, G.A.; Anderson, T.J.; Verma, S. Biomarkers of vascular disease linking inflammation to endothelial activation: Part II. Circulation 2003, 108, 2041–2048.
24. Zhang, R.; Brennan, M.L.; Shen, Z.; MacPherson, J.C.; Schmitt, D.; Molenda, C.E.; Hazen, S.L. Myeloperoxidase functions as a major enzymatic catalyst for initiation of lipid peroxidation at sites of inflammation. J. Biol. Chem. 2002, 277, 46116–46122.
25. Ross, R.; Glomset, J.A..Atherosclerosis and the arterial smooth muscle cell: Proliferation of smooth muscle cell is a key event in the genesis of the lesions of atherosclerosis. Science 1973, 180, 1332–1339.
26. Williams, K.J.; Tabas, I. The response-to-retention hypothesis of early atherogenesis. Arterioscler. Thromb. Vasc. Biol. 1995, 15, 551–561.
27. Proctor, S.; Vine, D.; Mamo, J., Arterial retention of apolipoprotein B(48)- and B(100)-containing lipoproteins in atherogenesis. Curr. Opin. Lipidol. 2002, 13, 461–470.
28. Stocker, R.; Frei, B. Endogenous antioxidant defenses in human blood plasma.In Oxidative Stress: Oxidants and Antioxidants.; Sies, H., Ed.; Academic Press: London, UK, 1991; pp. 213–243.
29. Cushing, S.D.; Berliner, J.A.; Valente, A.J.; Navab, M.; Parhami, F.; Gerrity, R.; Schwartz, C.J.; Fogelman, A.M..Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc. Natl. Acad. Sci. USA 1990, 87, 5134–5138.
30. Quinn, M.T.; Parthasarathy, S.; Fong, L.G.; Steinberg, D. Oxidatively modified low density lipoproteins: A potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc. Natl. Acad. Sci. USA 1987, 84, 2995–2998.
31. Shechter, I.; Fogelman, A.M.; Haberland, M.E.; Seager, J.; Hokom, M.; Edwards, P.A. The metabolism of native and MDA-altered LDL by human monocyte-macrophages. J. Lipid Res. 1981, 22, 63–71.
32. Hessler, J.R.; Robertson, A.L., Jr.; Chisolm, G.M., LDL-induced cytotoxicity and its inhibition by HDL in human vascular smooth muscle and endothelial cells in culture. Atherosclerosis 1979, 32, 213–229.
33. Cathcart, M.K.; McNally, A.K.; Chisolm, G.M. Lipoxygenase-mediated transformation of human LDL to an oxidized and cytotoxic complex. J. Lipid Res. 1991, 32, 63–70.
34. Mabile, L.; Salvayre, R.; Bonnafe, M.J.; Negre-Salvayre, A. Oxidizability and subsequent cytotoxicity of chylomicrons to monocytic U937 and endothelial cells are dependent on dietary fatty acid composition. Free Radic. Biol. Med. 1995, 19, 599–607.
35. Stadtman, E.; Berlett, B.S., Reactive oxygen-mediated protein oxidation in ageing and disease. Chem. Res. Toxicol. 1997, 10, 485–494.
36. Dedon, P.C.; Tannenbaum, S.R. Reactive nitrogen species in the chemical biology of inflammation. Arch. Biochem. Biophys. 2004, 433, 12–22.
37. Tarpey, M.M.; Wink, D.A.; Grisham, M.B., Methods for detection of reactive metabolites of oxygen and nitrogen: In vitro and in vivo considerations. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2004, 286, R431–R444.
38. Cracowski, J.L.; Durand, T.; Bessard, G. Isoprostanes as a biomarker of lipid peroxidation in humans: Physiology, pharmacology and clinical implications. Trends Pharmacol. Sci. 2002, 23, 230–236.
39. Draper, H.H.; Csallany, A.S.; Hadley, M. Urinary aldehydes as indicators of lipid peroxidation in vivo. Free Radic. Biol. Med. 2000, 29, 1071–1077.
40. Dean, R.T.; Fu, S.; Stocker, R.; Davies, M.J..Biochemistry and pathology of radical-mediated protein oxidation. Biochem. J. 1997, 324, 1–18.
41. Requena, J.R.; Levine, R.L.; Stadtman, E.R. Recent advances in the analysis of oxidized proteins. Amino Acids 2003, 25, 221–226.
42. Esterbauer, H.; Schaur, R.; Zollner, H. Chemistry and biochemistry of 4-hydroxynonenal, malondialdehyde and related aldehydes. Free Radic. Biol. Med. 1991, 11, 81–128.
43. Montuschi, P.; Barnes, P.J.; Roberts, L.J., Isoprostanes: Markers and mediators of oxidative stress. FASEB J. 2004, 18, 1791–1800.
44. Stocker, R.; Keaney, J.F., Jr. Role of oxidative modifications in atherosclerosis. Physiol. Rev. 2004, 84, 1381–1478.
45. Slatter, D.A.; Bolton, C.H.; Bailey, A.J. The importance of lipid-derived malondialdehyde in diabetes mellitus. Diabetologia 2000, 43, 550–557.
46. Heinecke, J.W. Oxidized amino acids: Culprits in human atherosclerosis and indicators of oxidative stress. Free Radic. Biol. Med. 2002, 32, 1090–1101.
47. Parola, M.; Bellamo, G.; Robino, G.; Barrera, G.; Dianzani, M.U. Hydroxynonenal as a biological signal: Molecular basis and pathophysiological implications. Antioxid. Redox Signal. 1999, 1, 255–284.
48. Shao, B.; O’Brien, K.D.; McDonald, T.O.; Fu, X.; Oram, J.F.; Uchida, K.; Heinecke, J.W. Acrolein modifies apolipoprotein A–I in the human artery wall. Ann. N. Y. Acad. Sci. 2005, 1043, 396–403.
49. Dalle-Donne, I.; Rossi, R.; Colombo, R.; Giustarini, D.; Milzani, A. Biomarkers of oxidative damage in human disease. Clin. Chem. 2006, 52, 601–623.
50. Giustarini, D.; Rossi, R.; Milzani, A.; Colombo, R.; Dalle-Donne, I. S-Glutathionylation: From redox regulation of protein functions to human diseases. J. Cell. Mol. Med. 2004, 8, 201–212.
51. Gaut, J.; Yeh, G.; Tran, H.; Byun, J.; Henderson, J.P.; Richter, G.M.; Brennan, M.-L.; Lusis, A.J.; Belaaouaj, A.; Hotchkiss, R.S.; et al., Neutrophils employ the myeloperoxidase system to generate antimicrobial brominating and chlorinating oxidants during sepsis. Proc. Natl. Acad. Sci. USA 2001, 98, 11961–11966.
52. Brennan, M.L.; Wu, W.; Fu, X.; Shen, Z.; Song, W.; Frost, H.; Vadseth, C.; Narine, L.; Lenkiewicz, E.; Borchers, M.T.; et al., A tale of two controversies: Defining both the role of peroxidases in nitrtyrosine formation in vivo using eosinophil peroxidase nad myeloperoxidase-deficient mice, and the nature of peroxidase-generated reactive nitrogen species. J. Biol. Chem. 2002, 277, 17415–17422.
53. Zheng, L.; Nukuna, B.; Brennan, M.; Brennan, M.L.; Sun, M.; Goormastic, M.; Settle, M.; Schmitt, D.; Fu, X.; Thomson, L.; Fox, P.L.; et al., Apolipoprotein A–I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J. Clin. Investig. 2004, 114, 529–541.
54. Pennathur, S.; Bergt, C.; Shao, B.; Byun, J.; Kassim, S.Y.; Singh, P.; Green, P.S.; McDonald, T.O.; Brunzell, J.; Chait, A.; et al., Human atherosclerotic intima and blood of patients with established coronary artery disease contain high density lipoprotein damaged by reactive nitrogen species. J. Biol. Chem. 2004, 279, 42977–42983.
55. Bergt, C.; Pennathur, S.; Fu, X.; Byun, J.; O’Brien, K.; McDonald, T.O.; Singh, P.; Anantharamaiah, G.M.; Chait, A.; Brunzell, J.; et al., The myeloperoxidase product hypochlorous acid oxidizes hdl in the human artery wall and impairs ABCA1 cholesterol transport. Proc. Natl. Acad. Sci. USA 2004, 101, 13032–13037.
56. Palinski, W.; Horkko, S.; Miller, E.; Steinbrecher, U.P.; Powell, H.C.; Curtiss, L.K.; Witztum, J.L. Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma. J. Clin. Investig. 1996, 98, 800–814.
57. Palinski, W.; Ord, V.A.; Plump, A.S.; Breslow, J.L.; Steinberg, D.; Witztum, J.L., ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis. Demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to malondialdehyde-lysine in serum. Arterioscler. Thromb. 1994, 14, 605–616.
58. Esterbauer, H.; Striegl, G.; Puhl, H.; Rotheneder, M. Continuous monitoring of in vitro oxidation of human LDL. Free Radic. Biol. Med. 1989, 6, 67–75.
59. Le, N.-A.; Farkas-Epperson, M.; Sweeney, M.; Wilson, P.; Brown, W. Effect of ABT-335 (fenofibric acid) on meal-induced oxidative stress in patients with metabolic syndrome. 2013, 231, 268–273.
60. McEneny, J.; O’Kane, M.J.; Moles, K.W.; McMaster, C.; McMaster, D.; Mercer, C.; Trimble, E.R.; Young, I.S. Very low density lipoprotein subfractions in type II diabetes mellitus: Alterations in composition and susceptibility to oxidation. Diabetologia 2000, 43, 485–493.
61. Hendrickson, A.; McKinstry, L.A.; Lewis, J.K.; Lum, J.; Louie, A.; Schellenberg, G.D.; Hatsukami, T.S.; Chait, A.; Jarvik, G.P. Ex vivo measures of LDL oxidative susceptibility predict carotid artery disease. Atherosclerosis 2005, 179, 147–153.
62. Ryglewicz, D.; Rodo, M.; Roszczynko, M.; Baranska-Gieruszczak, M.; Szirkowiec, W.; Swiderska, M.; Wehr, H. Dynamics of ldl oxidation in ischemic stroke patients. Acta Neurol. Scand. 2002, 105, 185–188.
63. McEneny, J.; Loughrey, C.M.; McNamee, P.T.; Trimble, E.R.; Young, I.S. Susceptibility of VLDL to oxidation in patients on regular haemodialysis. Atherosclerosis 1997, 129, 215–220.
64. Parks, E.J.; German, J.B.; Davis, P.A.; Frankel, E.N.; Kappagoda, C.T.; Rutledge, J.C.; Hyson, D.A.; Schneeman, B.O. Reduced oxidative susceptibility of LDL from patients participating in an intensive atherosclerosis treatment program. Am. J. Clin. Nutr. 1998, 68, 778–785.
65. Kaikkonen, J.; Porkkala-Sarataho, E.; Tuomainen, T.P.; Nyyssonen, K.; Kosonen, L.; Ristonmaa, U.; Lakka, H.M.; Salonen, R.; Korpela, H.; Salonen, J.T. Exhaustive exercise increases plasma/serum total oxidation resistance in moderately trained men and women, whereas their VLDL + LDL lipoprotein fraction is more susceptible to oxidation. Scand. J. Clin. Lab. Investig. 2002, 62, 599–608.
66. Nielsen, N.S.; Marckmann, P.; Hoy, C.E. Effect of meal fat quality on oxidation resistance of postprandial VLDL and LDL particles and plasma triacylglycerol level. Br. J. Nutr. 2000, 84, 855–863.
67. Parthasarathy, S.; Khoo, J.C.; Miller, E.; Barnett, J.; Witztum, J.L.; Steinberg, D. Low density lipoprotein rich in oleic acid is protected against oxidative modification: Implications for dietary prevention of atherosclerosis. Proc. Natl. Acad. Sci. USA 1990, 87, 3894–3898.
68. Reaven, P.; Parthasarathy, S.; Grasse, B.J.; Miller, E.; Almazan, F.; Mattson, F.H.; Khoo, J.C.; Steinberg, D.; Witztum, J.L. Feasibility of using an oleate-rich diet to reduce the susceptibility of low-density lipoprotein to oxidative modification in humans. Am. J. Clin. Nutr. 1991, 54, 701–706.
69. Reaven, P.; Parthasarathy, S.; Grasse, B.J.; Miller, E.; Steinberg, D.; Witztum, J.L., Effects of oleate-rich and linoleate-rich diets on the susceptibility of LDL to oxidative modification in mildly hypercholesterolemic subjects. J. Clin. Investig. 1993, 91, 668–676.
70. Olivecrona, T.; Egelrud, T. Lipoprotein lipase and its interaction with heparin. Horm. Metab. Res. 1974, 4, 23–28.
71. Fuki, I.V.; Blanchard, N.; Jin, W.; Marchadier, D.H.; Millar, J.S.; Glick, J.M.; Rader, D.J. Endogenously produced endothelial lipase enhances binding and cellular procesin of plasma lipoproteins via heparan sulfate proteoglycan-mediated pathway. J. Biol. Chem. 2003, 278, 34331–34338.
72. Quinn, D.; Shirai, K.; Jackson, R.L. Lipoprotein lipase: Mechanism of action and role in lipoprotein metabolism. Prog. Lipid Res. 1983, 22, 35–78.
73. Brown, W.W.; Baginsky, M.L. Some functional aspects of apolipoproteins: ApoLp-Ala inhibition of lipoprotein lipase and deinhibition by monoolein. Horm. Metab. Res. 1974, 4, 11–16.
74. Bengtsson, G.; Olivecrona, T. Lipoprotein lipase. Mechanism of product inhibition. Eur. J. Biochem. 1980, 106, 557–562.
75. Krauss, R.M.; Herbert, P.N.; Levy, R.I.; Fredrickson, D.S. Further observations on the activation and inhibition of lipoprotein lipase byapolipoproteins. Circ. Res. 1973, 33, 403–411.
76. Lambert, D.A.; Catapano, A.L.; Smith, L.C.; Sparrow, J.T.; Gotto, A.M., Effect of the apolipoprotein C-II/C-III1 ratio on the capacity of purified milk lipoprotein lipase to hydrolyze triglycerides in monolayer vesicles. Atherosclerosis 1996, 127, 205–212.
77. Le, N.A.; Cortner, J.A.; Breslow, J.L. Metabolism of intestinal lipoproteins during the postprandial state. In Diabetes; Rifkin, H., Colwell, J.A., Taylor, S.I., Eds.; Elsevier Science Publishers: New York, NY, USA, 1991; pp. 601–608.
78. Le, N.A.; Coates, P.M.; Gallagher, P.R.; Cortner, J.A. Kinetics of retinyl esters during postprandial lipemia in man: A compartmental model. Metabolism 1997, 46, 584–594.
79. Berman, M.; Hall, M., Levy, R.I.; Eisenberg, S.; Bilheimer, D.W.; Phair, R.D.; Goebel, R.H., Metyabolism of apoB and apoC lipoproteins in man: Kinetic studies in normal and hyperlipoproteinemic subjects. J. Lipid Res. 1978, 19, 38–56.
80. Le, N.A.; Li, X.; Kyung, S.; Brown, W.V. Evidence for the in vivo generation of oxidatively modified epitopes in patients with atherosclerotic endothelium. Metabolism 2000, 49, 1271–1277.
81. Gradek, W.Q.; Harris, M.T.; Yahia, N.; Davis, W.W.; Le, N.-A.; Brown, W.V. Polyunsaturated fatty acids acutely suppress antibodies to malondialdehyde-modified LDL in patients with vascular disease. Am. J. Cardiol. 2004, 93, 881–885.
82. Le, N.-A. Oxidized lipids and lipoproteins: Indices of risk or targets for management. Clin. Lipidol. 2009, 4, 41–54.
83. Palinski, W.; Miller, E.; Witztum, J.L. Immunization of LDL receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherosclerosis by mechanisms other than induction of high titers of antibodies to oxidative neoepitopes. Proc. Natl. Acad. Sci. USA 1995, 92, 821–825.
84. Nilsson, J.; Calara, F.; Regnstrom, J.; Hultgardh-Nilsson, A.; Ameli, S.; Cecek, B.; Shah, P.K. Immunization with homologous oxidized LDL reduces neointimal formation after balloon injury in hypercholesterolemic rabbits. J. Am. Coll. Cardiol. 1997, 30, 1886–1891.
85. Beisswenger, P.J.; Brown, W.V.; Ceriello, A.; Le, N.A.; Goldberg, R.B.; Cooke, J.P.; Robbins, D.C.; Sarwat, S.; Yuan, H.; Jones, C.A.; et al., Meal-induced increases in C-reactive protein, interleukin-6, and tumour necrosis factor α are attenuated by prandial + basal insulin in patients with Type 2 diabetes. Diabet Med. 2011, 28, 1088–1095.
86. Yagi, K., A simple fluorometric assay for lipoperoxide in blood plasma. Biochem. Med. 1976, 15, 212–216.
87. Yagi, K., Simple assay for the level of total lipid peroxides in serum or plasma. Methods Mol. Biol. 1998, 108, 101–106.
88. Davies, K.J.; Qunitanilha, A.T.; Brooks, G.A.; Packer, L. Free radicals and tissue damage produced by exercise. Biochem. Biophys. Res. Commun. 1982, 107, 1198–1205.
89. Close, G.L.; Ashton, T.; McArdle, A.; Maclaren, D.P.M. The emerging role of free radicals in delayed onset muscle soreness and contraction-induced muscle injury. Comp. Biochem Physiol Part A 2005, 142, 257–266.
90. Palomero, J.; Pye, D.; Kabayo, T.; Spiller, D.; Jackson, M. In situ detectioon and measurement of intracellular reactive oxygen species in single isolated mature skeletal muscle fiber by real time fluorescence microscopy. Antioxid Redox Signal 2008, 10, 1463–1474.
91. Trachootham, D.; Lu, D.; Ogasawara, M.A.; Nilsa, R.D.; Huang, P. Redox regulation of cell survival. Antioxid. Redox Signal. 2008, 10, 1343–1374.
92. Ji, L.L.; Gomez-Cabrera, M.C.; Vina, J. Role of free radicals and antioxidant signaling in skeletal muscle health and pathology. Infect. Disord. Drug Targets 2009, 9, 428–444.
93. Powers, S.K.; Talbert, E.E.; Adhihetty, P.J. Reactive oxygen and nitrogen species as intracellular signals in skeletal muscle. J. Physiol. 2011, 589, 2129–2138.
94. Allen, R.G.; Tresini, M. Oxidative stress and gene regulation. Free Rad. Biol. Med. 2000, 28, 463–499.
95. Ji, L.L.; Zhang, Y. Antioxidant and anti-inflammatory effects of exercise: Role of redox signaling. Free Radic. Res. 2014, 48, 3–11.
96. Morales-Alamo, D.; Calbet, J.A. Free radicals and sprint exercise in humans. Free Radic. Res. 2014, 48, 30–42.
97. Chyu, K.Y.; Shah, P. Can we vaccinate against atherosclerosis J. Cardiovasc. Pharmacol. Ther. 2014, 19, 77–82.
98. Salonen, J.T.; Yla-Herttuala, S.; Yamamoto, R.; Butler, S.; Korpola, H.; Salonen, R.; Nyyssonen, K.; Palinski, W.; Witztum, J.L. Autoantibody against LDL and progression of carotid atherosclerosis. Lancet 1992, 339, 883–887.
99. Maggi, E.; Finardi, G.; Poli, M.; Bollati, P.; Filipponi, M.; Stefano, P.L.; Paolini, G.; Grossi, A.; Clot, P.; Albano, E. Specificity of autoantibodies against oxLDL predicting myocardial infarction. Carotid Artery Dis. 1993, 4, 1119–1122.
100. Thavendiranathan, P.; Bagai, A.; Brookhart, M.; Choudhry, N. Primary prevention of cardiovascualr diseases with statin therapy: A meta-analysis of randomized controlled trials. Arch. Intern. Med. 2006, 166, 2307–2313.
101. Cholesterol Treatment Trialists’ (CTT) Collaborators; Kearney, P.M.; Blackwell, L.; Collins, R.; Keech, A.; Simes, J.; Peto, R.; Armitage, J.; Baigent, C., Cholesterol treatmnet trialists’ collaborators: Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials: A meta-analysis. Lancet 2008, 371, 117–125.
102. Sacks, F.M.; Pfeffer, M.A.; Moye, L.A.; Rouleau, J.L.; Rutherford, J.D.; Cole, T.G.; Brown, L.; Warnica, J.W.; Arnold, J.M.; Wun, C.C.; et al., The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial investigators. N. Engl. J. Med. 1996, 335, 1001–1009.
103. Albert, M.A.; Danielson, E.; Rifai, N.; Ridker, P.M. Effect of statin therapy on C-reactive protein levels: The pravastatin inflammation/CRP evaluation (PRINCE): A randomized trial and cohort study. JAMA 2001, 286, 64–70.
104. Ballantyne, C.M.; Hoogeveen, R.C.; Bang, H.; Coresh, J.; Folsom, A.R.; Heiss, G.; Sha, A.R. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (aric) study. Circulation 2004, 109, 837–842.
105. Koenig, W.; Khuseyinova, N.; Lowel, H.; Trischler, G.; Meisenger, C. Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: Results from the 14-year follow-up of a large cohort from southern Germany. Circulation 2004, 110, 1903–1908.
106. Blankenberg, S.; Zeller, T.; Saarela, O.; Havulinna, A.S.; Kee, F.; Tunstall-Pedoe, H; Kuulasmaa, K.; Yarnell, J.; Schnabel, R.B.; Wild, P.S.; et al., Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 poplation cohorts. Circulation 2010, 121, 2388–2397.
107. Yousuf, O.; Mohanty, B.D.; Martin, S.S.; Joshi, P.H.; Blaha, M.J.; Nasir, K.; Blumenthal, R.S.; Budoff, M.J. High-sensitivity C-reactive protein and cardiovascualr disease: A resolute belief or an elusive link. J. Am. Coll. Cardiol. 2013, 62, 397–408.
108. Le, N.A. Reducing oxidized lipids to prevent cardiovascular disease. Curr. Treatment. Options Cardiovasc. Med. 2008, 10, 263–272.
109. Tsimikas, S.; Aikawa, M.; Miller, F.J., Jr.; Miller, E.R.; Torzewski, M.; Lentz, S.R.; Bergmark, C.; Heistad, D.D.; Libby, P.; Witztum, J.L. Increased plasma oxidized phospholipid:apolipoprotein B-100 ratio with concomitant depletion of oxidized phospholipids from atherosclerotic lesions after dietary lipid-lowering: A potential biomarker of early atherosclerosis regression. Arterioscler. Thromb. Vasc. Biol. 2007, 27, 175–181.
110. Ky, B.; Burke, A.; Tsimikas, S.; Wolfe, M.L.; Tadesse, M.G.; Szapary, P.O.; Witztum, J.L.; Fitzgerald, G.A.; Rader, D.J. The influence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic humans. J. Am. Coll. Cardiol. 2008, 51, 1653–1662.
111. Nissen, S.E.; Tuzcu, E.M.; Schoenhagen, P.; Brown, B.G.; Ganz, P.; Vogel, R.A.; Crowe, T.; Howard, G.; Cooper, C.J.; Brodie, B.; et al., Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: A randomized controlled trial. JAMA 2004, 291, 1071–1080.
112. Choi, S.H.; Chae, A.; Miller, E.; Messig, M.; Ntanios, F.; DeMaria, A.N.; Nissen, S.E.; Witztum, J.L.; Tsimikas, S., Relationship between biomarkers of oxidized low-density lipoprotein, statin therapy, quantitative coronary angiography, and atheroma: Volume observations from the REVERSAL (Reversal of Atherosclerosis with Aggressive Lipid Lowering) study. J. Am. Coll. Cardiol. 2008, 52, 24–32.
113. Diwadkar, V.A.; Anderson, J.W.; Bridges, S.R.; Gowri, M.S.; Oelgten, P.R., Postprandial low-density lipoproteins in type 2 diabetes are oxidized more extensively than fasting diabetes and control samples. Proc. Soc. Exp. Biol. Med. 1999, 222, 178–184.
114. Tanaka, S.; Miki, T.; Sha, S.; Hirata, K.; Ishikawa, Y.; Yokohama, M. Serum levels of TBARS are associated with risk of coronary heart disease. J. Atheroscler. Thromb. 2011, 18, 584–591.
115. Walter, M.F.; Jacobs, R.F.; Jeffers, B.; Ghadanfar, M.M.; Gm Preston, J.B.; Mason, R.P. Serum levels of thiobarbituric acid reactive substances predict cardiovascular events in patients with stable coronary artery disease: A longitudinal analysis of the PREVENT study. J. Am. Coll. Cardiol. 2004, 44, 1996–2002.